Immupharma Plc-Product Pipeline Review-2015

Immupharma Plc-Product Pipeline Review-2015

  • Products Id :- GMDHC07224CDB
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Immupharma Plc-Product Pipeline Review-2015


Global Markets Direct's, 'Immupharma Plc-Product Pipeline Review-2015', provides an overview of the Immupharma Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immupharma Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Immupharma Plc including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Immupharma Plc's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Immupharma Plc's pipeline products

Reasons To Buy

Evaluate Immupharma Plc's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Immupharma Plc in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Immupharma Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Immupharma Plc and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immupharma Plc

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Immupharma Plc and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immupharma Plc Snapshot 5

Immupharma Plc Overview 5

Key Information 5

Key Facts 5

Immupharma Plc-Research and Development Overview 6

Key Therapeutic Areas 6

Immupharma Plc-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Immupharma Plc-Pipeline Products Glance 10

Immupharma Plc-Late Stage Pipeline Products 10

Phase III Products/Combination Treatment Modalities 10

Immupharma Plc-Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Immupharma Plc-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Immupharma Plc-Drug Profiles 14

forigerimod acetate 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

IPP-204106 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

IPP-102199 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

IPP-203101 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

IPP-201007 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Small Molecule for Undisclosed Indication 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Immupharma Plc-Pipeline Analysis 22

Immupharma Plc-Pipeline Products by Target 22

Immupharma Plc-Pipeline Products by Route of Administration 23

Immupharma Plc-Pipeline Products by Molecule Type 24

Immupharma Plc-Pipeline Products by Mechanism of Action 25

Immupharma Plc-Recent Pipeline Updates 26

Immupharma Plc-Discontinued Pipeline Products 28

Discontinued Pipeline Product Profiles 28

forigerimod acetate 28

Immupharma Plc-Company Statement 29

Immupharma Plc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

Immupharma Plc, Key Information 5

Immupharma Plc, Key Facts 5

Immupharma Plc-Pipeline by Indication, 2015 7

Immupharma Plc-Pipeline by Stage of Development, 2015 8

Immupharma Plc-Monotherapy Products in Pipeline, 2015 9

Immupharma Plc-Phase III, 2015 10

Immupharma Plc-Phase I, 2015 11

Immupharma Plc-Preclinical, 2015 12

Immupharma Plc-Discovery, 2015 13

Immupharma Plc-Pipeline by Target, 2015 22

Immupharma Plc-Pipeline by Route of Administration, 2015 23

Immupharma Plc-Pipeline by Molecule Type, 2015 24

Immupharma Plc-Pipeline Products by Mechanism of Action, 2015 25

Immupharma Plc-Recent Pipeline Updates, 2015 26

Immupharma Plc-Discontinued Pipeline Products, 2015 28

Immupharma Plc, Subsidiaries 31

List of Figures

Immupharma Plc-Pipeline by Top 10 Indication, 2015 7

Immupharma Plc-Pipeline by Stage of Development, 2015 8

Immupharma Plc-Monotherapy Products in Pipeline, 2015 9

Immupharma Plc-Pipeline by Top 10 Target, 2015 22

Immupharma Plc-Pipeline by Top 10 Route of Administration, 2015 23

Immupharma Plc-Pipeline by Top 10 Molecule Type, 2015 24

Immupharma Plc-Pipeline Products by Top 10 Mechanism of Action, 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Immupharma Plc; Immupharma Plc - Key Therapeutics; Immupharma Plc - Pipeline Overview and Promising Molecules; Immupharma Plc - News; Immupharma Plc - Latest Updates; Immupharma Plc - Pipeline; Immupharma Plc - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102450
Site License
USD 3000 INR 204900
Corporate User License
USD 4500 INR 307350



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]